(Q55067653)

16 June 2018

review article

1 reference

title

Steroid 5alpha-reductase inhibitors in androgen-dependent disorders. (English)

1 reference

16 June 2018

author name string

Harris GS

series ordinal

1

1 reference

16 June 2018

Kozarich JW

series ordinal

2

1 reference

16 June 2018

publication date

1 August 1997

1 reference

16 June 2018

Current Opinion in Chemical Biology

published in

1 reference

16 June 2018

volume

1

1 reference

16 June 2018

issue

2

1 reference

16 June 2018

page(s)

254-259

1 reference

16 June 2018

Steroid 5 alpha-reductase: two genes/two enzymes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Pharmacological options in the treatment of benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Mechanistic studies with solubilized rat liver steroid 5 alpha-reductase: elucidation of the kinetic mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

4-Aza-3-oxo-5 alpha-androst-1-ene-17 beta-N-aryl-carboxamides as dual inhibitors of human type 1 and type 2 steroid 5 alpha-reductases. Dramatic effect of N-aryl substituents on type 1 and type 2 5 alpha-reductase inhibitory potency

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Mechanism of Time-Dependent Inhibition of 5.alpha.-Reductases by .DELTA.1-4-Azasteroids: Toward Perfection of Rates of Time-Dependent Inhibition by Using Ligand-Binding Energies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

4,7 beta-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type 1 5 alpha-reductase.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

MK386: a potent, selective inhibitor of the human type 1 5alpha-reductase

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Finasteride: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Design of the Prostate Cancer Prevention Trial (PCPT).

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Cell type specific expression of steroid 5 alpha-reductase 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Identification and selective inhibition of an isozyme of steroid 5 alpha-reductase in human scalp

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Immunohistochemical evidence for differential distribution of 5 alpha-reductase isoenzymes in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Androgen production and skin metabolism in hirsutism

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Clinical relevance of testosterone and dihydrotestosterone metabolism in women

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Treatment of hirsutism with the pure antiandrogen flutamide

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Treatment of hirsutism with spironolactone

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Prolonged treatment with finasteride (a 5α‐reductase inhibitor) does not affect bone density and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

5alpha-reductase 1 and 2 expression and activity in human ovarian follicles, stroma and corpus luteum as compared to neonatal foreskin

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2897%2980017-8

7 January 2021

10.1016/S1367-5931(97)80017-8

Identifiers

DOI

1 reference

16 June 2018

release_uhp34vcddnb5rnemcbu6t4nbji

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uhp34vcddnb5rnemcbu6t4nbji

24 November 2022

mapped directly with Wikidata item

1 reference

16 June 2018